What is Surufatinib?

Surufatinib is a targeted therapy drug primarily used to inhibit neuroendocrine tumors, with specific details as follows:

The main formulation of surufatinib is capsules, and it belongs to the class of oral tyrosine kinase inhibitors. For patients with pancreatic or non-pancreatic neuroendocrine tumors that are unresectable by surgery or have already metastasized, medications containing surufatinib are generally prescribed under medical supervision to suppress disease progression. Surufatinib is classified as an antitumor agent and also falls within the category of targeted drugs. It exerts inhibitory effects on vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), thereby enhancing immune function and suppressing or improving the condition.

To avoid excessive adverse reactions and ensure optimal drug efficacy, this medication should be taken strictly under the guidance of a physician.